Gene editing technology demonstrating ability to analyse and edit genetic information of living organisms is anticipated to further leverage tremendous growth in the global gene editing technology market

Gene editing technology is a scientific evolution that is used to change or edit the DNA of animals, humans, plants, mammals including other living organisms. Gene editing is referred to the ability for DNA sequencing. For example, DNA repair process in human embryos. The introduction of CRISPR-Cas9 system leading to current surge and rise in applications are driving the global gene editing market.

In addition to this, gene editing positively impacting sustainable development, environmental management, food security, better diagnostics and therapeutics are boosting the market growth. This has led to extensive rise in current market revenue and is expected to reach close to USD 19.45 billion until 2028.

However, legalities involved in genome editing, failure in targeting specific cells, challenges in efficient delivery of genes and gene editing tools are likely to significantly impact the global gene editing market. Nevertheless, technology penetration for efficient cell targeting, government support, R&D activities, and investment remains strong. Moreover, introduction of efficient tools and delivery methods enabling long-term alterations, new breakthroughs going beyond traditional approach are anticipated to support gene editing industry in the next five years.

The current and future of gene editing technology is promising with rapid evolutions in the industry. Most importantly efforts by governments and private organization are being made to encourage R&D programs in gene editing, and genome engineering field.

Also, applications through development of new tools, processes, and platforms for genome editing, upgradations in existing methods, and new applications of genome editing in agriculture, medical, environmental and many other fields are introduced. These factors are propelling the global gene editing market.

The Adroit Market Research Report aims to establish a reliable and accessible platform for market players seeking factual, thorough researched, up-to-date information for making quick and better business decisions in the global gene editing market. The report studies the state-of-the-art genome editing technologies, latest developments, improvements in existing genome editing methods, market dynamics, and all the important areas in the gene editing technology market are focused in the report.

The report gives market size information for supporting planning and investment decisions of market players and analyses each market aspect through SWOT, PEST, and STEER analysis. The report also looks at the competitive environment and supply chain dynamics of Gene Editing technology. It studies the key performance indicators and operational metrics to help market players benchmark against other businesses.

The market leading companies have majorly contributed to the current upsurge and range of applications of gene editing. The companies are optimistic about gene editing given their capital investment and focus on technology integrations. These companies are ranked on the basis of their previous revenues, sales of products and services, R&D initiatives, and other strategic initiatives.

The CRISPR-Cas9 system accounted for maximum share of global gene editing market as it is enabling precise, targeted, and effortless changes in the DNA sequence. The introduction of CRISPR-Cas9 system has led to current market upsurge and increasing number of applications of genome editing technologies. The uniqueness of CRISPR-Cas9 has encouraged its quick inclusion across applications.

The biotechnology & pharmaceutical companies contributed to largest revenue in global gene editing market. High penetration of genomics technology for better editing of DNA of living organisms, rapid investments, and efficiency of gene therapies, and significant investments in technology made by the biotechnology & pharmaceutical companies has boosted their market share.

A larger market share proportion is contributed by North America to the global gene editing market growth. The North America has presence of recognized academic or world-class research facilities, strong R&D linkages and collaborations, rapid adoption of applications, and high disposable incomes.

Asia Pacific is also a good market shareholder in gene editing technology as the governments in this region have increased funding, supporting research initiatives, and awareness of benefits of gene editing technology for humans, and other living organisms is increasing.

The top companies contributing to gene-editing based research and development of innovative genome editing methods are AstraZeneca, OriGene, New England Biolabs, GenScript, Egenesis, Integrated DNA Technologies, Horizon Discovery, Takara Bio, Cellectis, Intellia, Caribou, CRISPR, Precision Biosciences, Editas Medicine, Sangamo, Cibus, Merck, and KGaA among others.

Key Segments of the Global Gene Editing Market

Type Overview, 2018-2028 (USD Billion)

• Zinc finger nucleases (ZFNs)
• Transcription Activator-Like Effector-based Nucleases (TALENs)
• CRISPR-Cas system

Application Overview, 2018-2028 (USD Billion)

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Contract Research Organizations

Regional Overview, 2018-2028 (USD Billion)

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

South America

• Brazil
• Mexico
• Rest of South America

Middle East and Africa